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Abstract 
Background/Aims: The prolongation of the QT interval and dispersion could predict 
ventricular arrhythmias. It is not yet established whether there is a difference between the 
effects of hemodialysis and hemodiafiltration on QT interval duration and dispersion.  
Methods: Data of thirty patients was investigated while they were receiving hemodiafiltration 
over a period of three months then the same group of patients was evaluated during treatment 
with conventional hemodialysis for at least another three months. Ionic parameters, surface 
electrocardiograms (ECG) were analyzed five times during each session, and 2D, M-mode 
echocardiography, Holter ECGs were performed to acquire additional information. 
Results: QT interval duration (QTmax) and dispersion (QTd) showed a significant increase 
during hemodialysis, but not during hemodiafiltration. QTmax was 388.66±31.81 msec at the 
beginning of hemodialysis, and increased to 400.66±39.12 msec even at the 30th minute 
(p<0.05). QTd was found to be 31.33±10.08 msec before the commencement of hemodialysis 
with the largest prolongation being seen at the 240
th
 minute (51.33±14.56 msec, p<0.05). The 
occurrence of ventricular premature beats was significantly higher during hemodialysis 
(p=0.018). The left atrial diameter significantly decreased at the end of hemodiafiltration (at 
the beginning 45.1±5.25 mm, at the end 40.77±5.76 mm; p<0.05). 
Conclusion: Our results suggest a beneficial effect of hemodiafiltration on the studied 
electrocardiographic parameters compared to hemodialysis. The larger decrease in the left 
atrial diameter suggests a more efficient intracardiac volume decreasing potential of 
hemodiafiltration. 
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Introduction 
QT interval represents the electrical repolarization of the ventricular myocardium. It is 
dependent on the ventricular rate (the faster the heart rate the shorter it is) and can improve 
the detection of patients at increased risk of life threatening ventricular dysrhythmias. The QT 
interval duration varies between leads on the standard surface electrocardiogram. These 
interlead differences called QT dispersion, which is an index of the spatial dispersion of the 
ventricular recovery times, and can distinguish between myocardium that is homogeneous 
from myocardium that displays increased prolongation of repolarization [1–5] Several studies 
have highlighted the increased susceptibility of developing ventricular arrhythmias during 
hemodialysis. Cardiovascular mortality accounts for 40% of all deaths of patients suffering 
from kidney failure, where sudden cardiac death occurs in approximately 60% of patients 
undergoing hemodialysis[6,7]. Whereas conventional hemodialysis eliminates mostly small 
molecular weight uremic toxins by diffusion, hemodiafiltration has the advantage of 
eliminating higher molecular weight toxic polypeptides by convective transport. In 
comparison to hemodialysis, the quality of life is superior and mortality rates are lower in the 
case of hemodiafiltration[8–10]. Moreover despite the huge changes with regard to volume 
status the quality of life is improved and mortality rates are lower in the case of 
hemodiafiltration. However, the effects of hemodiafiltration on ventricular arrhythmia 
tendency have not yet been elucidated. Also, it is not clear to what extent the changes in 
ventricular arrhythmia susceptibility affect the mortality rate, compared to conventional 
hemodialysis. Therefore, the question is whether electrocardiographic markers, reflecting 
ventricular repolarization, differ with renal replacement modalities.  
 
Patients and methods 
Thirty patients, with end stage renal failure were enrolled during a single center study from 
our extracorporeal center (18 males, 12 females, mean age 60.5713.62 years, range 23-85 
years). Firstly, we collected and analyzed the data of the patients while they were under 
hemodiafiltration for three months, then the same patients were treated with conventional 
hemodialysis for at least another three months. This was followed, at the time of the regular 
hemodialysis, by another data collection. All diseases which can affect pulse generation and 
conduction of the heart were exclusion criteria. Thus, patients with amyloidosis, sarcoidosis, 
carcinoid, hemochromatosis, diabetes mellitus or Parkinson’s disease were not involved in our 
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investigations. QT interval may be affected by genetic causes (long QT syndrome, short QT 
syndrome), moreover the prolongation of the QT interval may be the consequence of drug 
interaction (e.g. haloperidol, methadone, amiodarone, sotalol, selective serotonine reuptake 
inhibitors, macrolide antibiotics, and antifungal agents). Likewise, hypothyroidism and altered 
calcium metabolism may affect this electrocardiographic parameter. Patients on these 
medications and/or suffering from such endocrine disorders were also not involved in the 
study. None of our patients suffered from inherited long or short QT syndrome. Patients with 
atrial fibrillation were also excluded. Patients suffering from end stage kidney disease (Stage 
5) participating in regular hemodialysis program in our center, and were willing to give their 
informed consent to take part in the investigations were included. Chronic renal failure was 
caused by the following: chronic glomerulonephritis (n=5), hypertensive and vascular 
nephropathy (n=12), chronic pyelonephritis (n=1), polycystic kidney disease (n=2), analgesic 
nephropathy (n=3), renal agenesis (n=1), lupus nephritis (n=2), and vasculitis (n=4). Clinical 
data of the study population are shown in Table 1. All patients gave informed consent to 
participate in the study and the Institutional Ethics Committee on Human Research approved 
the study protocol. Hemodialysis and hemodiafiltration were performed three times a week in 
4-hour long sessions with Fresenius 4008 S and H machines (Fresenius Medical Care, Bad 
Homburg, Germany), and with Fx60 and Fx80 high-flux polysulfone dialyzers (Fresenius). 
During hemodiafiltration 15.16±5 liters of ultrafiltrate was removed. All of our patients were 
treated with post-dilution method during hemodiafiltration sessions. The replacement solution 
was manufactured on-line from ultrapure water and consisted of 138 mmol/L sodium, 2 or 3 
mmol/L potassium (in 13 cases 2 mmol/l in 17 cases 3 mmol/l), 1.5 mmol/L calcium, 0.5 
mmol/L magnesium, and 1 g/L glucose. The blood flow was 338±11.6 ml/min and did not 
differ significantly during the respective procedures (p<0.05). The bicarbonate dialysis 
solution contained the same concentrations. During the sessions no drugs other than isotonic 
sodium chloride and sodium heparin solutions were used. The serum ion levels were 
measured four times during the sessions and 2 hours afterwards. The arterial blood pressure 
was monitored non-invasively. The conventional 12-lead ECGs were performed five times in 
each case: at the beginning of the treatment, and in the 15
th
, 30
th
 and the 240
th
 minutes, and 
two hours after the end of the sessions. Electrocardiograms were recorded at 25 mm/sec 
recording speed (Hewlett Packard Page Writer 200i) while the patients were in the supine 
position. Copies of the recordings were made with a magnifying factor of 3; in every lead 
three QT intervals were measured. In order to eliminate the inter-observer variability the 
values were calculated with calipers by one examiner in a blinded fashion. The end of the T-
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wave was determined as the beginning of the TP interval; in the case of the U-waves, the 
deepest point between the T- and U-waves marked the end of the interval. Three consecutive 
sections were defined, then their average was calculated and the resulting value used as the 
QT value in the given lead. In the statistical analysis, the longest QT value of the 12 leads was 
used as the QT interval (QTmax), and the QT dispersion (QTd) was determined as the 
difference between the longest and shortest QT interval. The QT interval and QTd were 
corrected to heart rate (QTmax c, QTd c) according to Bazett’s formula: QTmax c = QT/RR 
(msec). Before and after the renal replacement therapy transthoracic echocardiography (M-
mode, 2D) were performed with pulsed and continuous wave Doppler technique (Philips ATL 
HDI 5000 imaging system with a 3.5 MHz transducer was used). During the examinations left 
atrial cross diameter and left ventricular ejection fraction were determined (Simpson's 
formula). Left ventricular mass index was calculated with the equation suggested by 
Devereux and Reichek ({1.04x [(end-diastolic diameter of the left ventricle + interventricular 
septum thickness + the posterior wall thickness of the left ventricle)
 3
-end-diastolic diameter 
of the left ventricle
3
] -14}/height). Holter-ECGs (GE Medical SEER Light) were performed to 
assess ventricular arrhythmias, and were started before the therapy and ended 24 hours 
afterwards thus, both intra- and interdialytic periods were monitored. The number of 
ventricular premature beats was compared to the total number of beats and the resulting 
modulus was used to eliminate the variations arising from the short differences between the 
duration of the examinations. 
 
Statistical analysis 
The statistical analysis was carried out with the help of SAS 8.2 for Windows.  
The variations of the investigated parameters over time and the differences between the two 
modalities were investigated by using ANOVA. The correlations between the parameters 
were analyzed by using the Pearson test when the distribution was normal and by Spearman’s 
rank test in the case of an abnormal distribution. Throughout the analysis the p <0.05 
probability level was considered to be statistically significant. 
 
Results 
All electrocardiographic parameters showed an increase during hemodialysis (p<0.05), but no 
significant changes were observed during hemodiafiltration. Even all the starting ECG 
parameters were significantly longer in case of hemodiafiltration compared to hemodialysis 
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(QTmax p<0.0001, QTc p<0.0001, QTd p=0.0034, QTd c p=0.003). Nevertheless, all of the 
studied electrocardiographic markers were found to be within the physiologic range at the 
beginning of the sessions. Neither QTmax and the QTd nor QTmax c and QTd c showed 
significant changes during the first 30 minutes of the hemodialysis, but from the 30
th
 minute 
prolongation was observed in all parameters (p<0.05). The average value of QTmax was 
388.66±31.81 milliseconds (msec) at the beginning of hemodialysis, and increased to 
400.66±39.12 msec by the 30th minute (p<0.05) and reaching its maximum value by the 240th 
minute of the hemodialysis (418.67±46.07 msec, p<0.05), QTmax remained prolonged, 
compared to the base value (391.33±43.2 msec) (p<0.05) 2 hours following the hemodialysis. 
The mean value of the QTd was found to be 31.33±10.08 msec before the commencement of 
the hemodialysis with the largest prolongation being seen at the 240
th
 minute (51.33±14.56 
msec, p<0.05); this value, compared to the base value, was still persistently prolonged at 
34.66±12.79 msec two hours following the treatment. QTmax c had lengthened from the base 
value of 435.4±28.42 msec to 454.93±32.76 msec at thirty minutes, and this value kept on 
increasing. Even after these values started decreasing, we still found that the prolongation was 
significant 2 hours after the treatment (453.26±28.00 msec, p<0.05). QTd c rose from 
34.96±10.95 msec to 43.46±13.28 msec in the first half hour of the hemodialysis (p<0.05) and 
reached its maximum value by the 240
th
 minute (58.27± 15.54 msec, p<0.05). In contrast, the 
parameters of the QT interval did not change significantly during the hemodiafiltration 
(Figures 1. and 2.). The total calcium and ionized calcium showed an increase (p<0.05), 
while serum potassium, magnesium and phosphate concentrations decreased significantly 
during both renal replacement modalities (HDF p<0.05, HD: p<0.05). However, we did not 
find significant differences between hemodialysis and hemodiafiltration regarding these 
parameters (Table 2.). During hemodiafiltration sodium levels did not change significantly, 
however, in the case of hemodialysis a decrease was observed in the 15
th
 and 30
th
 minutes 
(p<0.05) compared to the baseline levels (Figure 3.). During hemodiafiltration, a negative 
correlation was seen between both the total calcium and ionized calcium levels, and the 
QTmaxc; while in the case of hemodialysis the serum sodium concentration and the QTmaxc 
showed a positive correlation (Table 3.). Changes in ventricular rate were characterized by 
the RR cycle length. During hemodiafiltration the RR length was increased (852±104.3 msec, 
p<0.05) at the 30
th
 minute, indicating the provisional decrease of the heart frequency, and then 
it decreased. In the case of hemodialysis, the RR cycle length was observed to decrease 
(800.6±96.2 vs. 746.6±125.5 msec, p<0.05) 2 hours after treatment (Figure 4.). Regarding 
blood pressure in both treatment modalities a rapid decrease occurred after the start of the 
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sessions, which compared to baseline values, reached a significant level by the 15
th
 minute. 
The systolic blood pressure did not change significantly after this, however, the diastolic 
values showed an increase after the treatment. During hemodiafiltration the systolic and 
diastolic values were higher even at the initial stages of the sessions. (Figures 5/a. and 5/b.) 
At the beginning there were no significant differences in left atrial diameter between the two 
modalities, however, by the end of hemodiafiltration a decrease was observed (p<0.001). In 
contrast, similar changes were not found during hemodialysis (p=0.11) (Figure 6.). Regarding 
end diastolic left ventricular diameter and the left ventricular ejection fraction no differences 
or changes were observed in either of the treatments. Body weight and body mass index 
(BMI) decreased significantly in both modalities (Table 4.). Importantly, the effective volume 
removals did not differ significantly between the two renal replacement modalities. During 
both therapies positive correlations were found between the left ventricular mass index, and 
the QTmax, QTmaxc, and QTd (p<0.05) (Table 5.). No malignant ventricular arrhythmias 
appeared, but the occurrence of ventricular premature beats was significantly higher during 
hemodialysis (p=0.018) (Table 6.). The ratio of ventricular premature beats to the total 
number of heart beats differed significantly (Figure 7.). There were no significant 
correlations between QT parameters and premature ventricular complexes, while in the case 
of hemodialysis QTmax and QTc correlated positively with the number of premature atrial 
complexes (Table 7.). The left ventricular ejection fraction correlated negatively with the 
number of ventricular premature beats in both treatment modalities (HDF r=-0.55, p=0.0015, 
HD r=-0.36, p=0.046). 
 
 
Discussion 
The lengthening of the QT interval and dispersion may result in an increased risk of malignant 
ventricular arrhythmias and the danger of sudden cardiac death[11–13]. Mortality rate of 
patients on chronic hemodiafiltration programs is 35% lower than those receiving 
hemodialysis[14]. Previously, it has been shown that in the case of hemodiafiltration the 
clearance of small- and medium- molecular weight substances is higher compared to 
conventional treatment , and the concentrations of acute phase proteins, and inflammatory 
mediators (C-reactive protein, interleukin-1, -6, β-2 microglobulin) do not rise during such 
treatments or thereafter[15–18]. The suppression of inflammatory reactions may contribute to 
the positive changes in the frequency of anemia during hemodiafiltration. Besides the known 
factors, it could be also evaluated that patients receiving hemodiafiltration treatment for their 
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renal disease better enjoy the benefits resulting from the reduction in arrhythmia incidences 
and from the slower progression of the cardiac target organ damage[19,20]. In our 
investigation hemodiafiltration did not cause significant changes in QT parameters, while 
hemodialysis significantly lengthened all the studied ECG markers. This difference suggests 
the beneficial effect of hemodiafiltration on the ventricular repolarizational 
electrocardiographic markers. This can be the consequence of various causes. On one hand 
the significant positive correlation between the QTmaxc and the sodium during hemodialysis 
directs the attention to the possible effects of the changes in electrolyte concentrations. On the 
other hand the increase in ventricular frequency observed during hemodialysis could be the 
result of the differences in the intravascular and intracardiac dynamics of the volume state 
between the two renal replacement therapies. Furthermore, the larger decrease in the left atrial 
diameter during hemodiafiltration suggests that hemodiafiltration might have a more efficient 
intracardiac volume decreasing potential; however there was no significant difference in the 
effective volume removals between the two modalities. As no significant differences were 
observed between the two modalities regarding serum potassium, magnesium and phosphate 
we conclude that the altered behavior of electrocardiographic parameters during the different 
renal replacement therapies do not likely to be caused by the changes in these ionic 
parameters. Furthermore, during hemodiafiltration, a negative correlation was seen between 
both the total calcium and ionized calcium levels and the QTmaxc. Moreover, in the case of 
hemodialysis the serum sodium and the QTmaxc showed a significant positive correlation. 
These results suggest that the alterations of these arrhythmia markers may be the result of the 
coexistence of certain ionic imbalances and renal replacement methods. Also, this 
phenomenon highlights the importance of the careful control of these ionic parameters and the 
potential benefits of electrolyte profiling over the course of the sessions in order to prevent 
electrocardiographic changes and to lower the risk of arrhythmogenesis. The possible reasons 
for the significant differences in QT parameters observed between the two modalities even at 
the beginning of treatments have not been clearly established and needs further investigation. 
The left ventricular mass index, QTmax, QTmaxc, and QTd showed a positive correlation 
regardless of the type of renal replacement modality, which confirms the role the 
myocardium’s mass growth plays in arrhythmogenesis. Although malignant ventricular 
arrhythmias were not observed in any one of the modalities applied, ventricular premature 
complexes appeared significantly more often during hemodialysis. No significant correlations 
were found between QT parameters and premature ventricular complexes, while in the case of 
hemodialysis QT and QTc correlated positively with premature atrial complexes. These 
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results attract the attention to the possible role of the increased atrial and ventricular 
intracardiac pressures and myocardial wall stress in the genesis of both atrial and ventricular 
arrhythmias in the case of conventional hemodialysis. A degree of similarity between the 
volume removals might be indicated by the kinetics in the changes of blood pressure, but the 
systolic and diastolic data showed significant differences even at the start of the treatments, 
which may affect the results. The relationship between the left ventricular systolic dysfunction 
and the tendency to ventricular arrhythmias has been confirmed by our results, and this was 
found to be valid in both renal replacement modalities. 
 
Conclusion 
During hemodiafiltration, in contrast to hemodialysis, the studied electrocardiographic 
markers do not change significantly. This might be the result of a more balanced but increased 
intracardiac and intravascular volume reductions, the more effective balancing of the sodium 
concentration, and the already proven powerful antioxidant and anti-inflammatory effects, 
positive influence on the lipid profile, the more efficient removal of the small and medium 
molecular-weight solutes and uremic toxins that can be observed during hemodiafiltration.  
 
Study limitation 
The number of the studied patients is relatively small, however all patients suitable for clinical 
investigations were enrolled from our center. The determination of long term effects of 
hemodiafiltration on cardiac arrhythmias was not possible during the present study, so further 
investigations are needed to get a clearer picture on this issue. Our results apply only to our 
selected group of patients with a low frequency of coronary artery disease. 
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Figure legend 
 
Figure 1. During hemodiafiltration, the maximal QT interval (QTmax) and the corrected 
maximal QT interval (QTmaxc) did not change significantly, however, at the 30
th
 minute of 
the hemodialysis these values became prolonged compared to the baseline levels. (*p<0.05)  
 HD: hemodialysis, HDF: hemodiafiltration 
Figure 2. During hemodialysis the QT dispersion (QTd) and the corrected QT dispersion 
(QTdc) are prolonged in the 30
th
 minute, while in the case of hemodiafiltration no changes are 
observed. (*p<0.05) HD: hemodialysis, HDF: hemodiafiltration 
Figure 3. At the 15
th
 and 30
th
 minutes of the hemodialysis the sodium concentration showed a 
significant decrease compared to the baseline (*p<0.05), however, there was no similar 
difference observed in the case of hemodiafiltration.  
HD: hemodialysis, HDF: hemodiafiltration 
Figure 4. The RR cycle length showed a significant prolongation by the 30
th
 minute of the 
haemodiafiltration, on the other hand, we observed a decrease in the 2
nd
 hour after 
hemodialysis. (*p< 0.05) HD: hemodialysis, HDF: hemodiafiltration 
Figures 5/a. and 5/b. The changes in systolic and diastolic blood pressures (BP) during the 
different methods of renal replacement. (*=p<0.05)  
HD: hemodialysis, HDF: hemodiafiltration 
Figure 6. The left atrial diameter significantly decreased during hemodiafiltration. 
HD: hemodialysis, HDF: hemodiafiltration (*=p<0.05) 
Figure 7. The ratio of ventricular premature beats (VPBs) was significantly higher in the case 
on conventional hemodialysis. 
(*p<0.05) HDF: hemodiafiltration, HD hemodialysis 
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Table 1. Clinical data of the studied population 
 
Gender (male/female) 18/12 
Mean age (years) 60.57 ± 13.62 
Duration of renal replacement therapy 
(months) 
93.13 ± 70.09 
Hypertension 27/30 (90%) 
Myocardial infarction 3/30 (10%) 
Ischemic heart disease 3/30 (10%) 
Hyperlipidemia 5/30 (16.7%) 
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Table 2. Laboratory and echocardiographic data of the studied population. 
* indicate significant changes regarding echocardiographic parameters and laboratory 
findings compared to the baseline (p<0.05). LAD: left atrial diameter, LVMI: left 
ventricular mass index, EF: left ventricular ejection fraction, HD: hemodialysis, HDF: 
hemodiafiltration 
 
 
 HD HDF 
Before session End of session Before session End of session 
[Na
+
] (mmol/l) 143.7±3.2 142.86±3.3 143.1±4.3 142±3.2 
[K
+
] (mmol/l) 5.29±0.6 3.8±0.28* 5.04±0.7 3.75±0.3* 
[Mg
++
] (mmol/l) 1±1.13 0.85±0.06* 1±0.13 0.87±0.06* 
[Ca
++
] (mmol/l) 1.18±0.12 1.31±0.06* 1.16±0.11 1.31±0.07* 
[Ca total] (mmol/l) 2.15±0.2 2.39±0.13* 2.13±0.18 2.34±0.11* 
[PO4
2-
] (mmol/l) 1.61±0.56 0.73±0.23* 1.56±0.33 0.72±0.18* 
urea (mmol/l) 22.37±7.2 8.58±3.1* 20.91±5.1 7.8±2.3* 
kreatinine (μmol/l) 766±182 402±105* 761.7±182 383±100* 
LAD (mm) 45.1±6.5 43.43±5.8 45.43±5.2 40.77±6* 
septum (mm) 13.67±1.87 13.7±1.3 13.97±2.1 13.4±2.1 
posterior wall (mm) 13.03±1.6 13.17±1.2 13.57±1.7 13.27±1.7 
LVMI (g/m
2
) 211±69 193±64 188±62 185±65 
EF (%) 56.57±9.2 56±7.7 56.47±8.7 54.57±6.8 
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Table 3. The correlating coefficients describing the relation between QT parameters and ionic 
markers. The investigation was independent of time (Spearman’s rank analysis) (*p<0.05). 
HD: hemodialysis, HDF: hemodiafiltration, tCa: serum total calcium, iCa: serum ionized 
calcium 
 
HDF QTmax QTmaxc QTd QTdc 
Na
+
 0.13928 0.1497 -0.14895 -0.21304 
K
+
 0.21096 0.28614 -0.11274 -0.11117 
Mg
2+
 0.07835 0.02973 0.10157 0.1498 
tCa -0.27192 -0.54647* -0.03585 -0.04488 
iCa
2+
 -0.30389 -0.50775* -0.09232 -0.09422 
PO4
2-
 0.11576 0.21603 0.08655 0.12102 
HD QTmax QTmaxc QTd QTdc 
Na
+
 0.36653 0.46199* 0.13464 0.0578 
K
+
 0.12411 0.07758 -0.01079 -0.16192 
Mg
2+
 0.04189 -0.04976 0.23717 0.09602 
tCa -0.17572 -0.0128 0.11822 0.11421 
iCa
2+
 0.03974 0.1641 -0.05534 -0.02377 
PO4
2-
 0.27964 0.11821 0.31424 0.12578 
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Table 4. Body weight (BW) and body mass index (BMI) before and after hemodialysis (HD) 
and hemodiafiltration (HDF). * indicate significant changes compared to the baseline 
(p<0.05). Volume removals between hemodialysis and hemodiafiltration did not differ 
significantly. 
 
 BW before (kg) BW after (kg) BMI before BMI after 
HD 67.47 ±14.44 65.3± 14.74* 24.4± 4.2 23.6 ±4.3* 
HDF 67.4 ±14.34 65.29± 14.33* 24.38 ±4.12 23.6± 4.14* 
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Table 5. The relation between QT parameters and the left ventricular mass index (Spearman’s 
rank analysis). Correlational coefficients (r values) are shown (* p<0.05) 
HD: hemodialysis, HDF: hemodiafiltration 
 
 
QT parameter r value HDF r value HD 
QTmax 0 minute *0.48933 *0.61147 
QTmax 15 minute *0.45200 *0.50164 
QTmax 30 minute *0.45073 0.35027 
QTmax 240 minute *0.42758 *0.49368 
QTmax after HD *0.37065 *0.55224 
QTmax c 0 minute *0.52783 *0.53015 
QTmax c 15 minute 0.31079 0.40198 
QTmax c 30 minute *0.45692 *0.43128 
QTmax c 240 minute *0.46994 *0.38955 
QTmax c after HD 0.30301 *0.39777 
QTd 0 minute 0.20413 0.10882 
QTd 15 minute 0.17227 0.31938 
QTd 30 minute 0.14779 0.32537 
QTd 240 minute *0.45874 *0.40144 
QTd after HD 0.18338 -0.11899 
QTd c 0 minute 0.02905 0.01096 
QTd c15 minute -0.01944 0.14868 
QTd c 30 minute -0.01220 0.27103 
QTd c 240 minute 0.34950 0.25348 
QTd c after HD 0.12099 -0.30186 
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Table 6. Number of premature atrial complexes (PVCs) and premature ventricular complexes 
(PVCs) during hemodialysis and hemodiafiltration. The occurrence of PVCs was significantly 
higher during hemodialysis. The number of premature atrial complexes was higher in the case 
of hemodialysis, but this difference did not prove to be significant. * p<0.05 
 
 Number of PACs Number of PVCs 
HD 363.6± 690 256.2 ±657* 
HDF 350.4± 765 183.1± 476 
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Table 7. Significant correlations between electrocardiographic variables and premature atrial 
complexes during hemodialysis (r values showing correlations between the studied 
parameters). No such significant correlations were found during hemodiafiltration.* p<0.05. 
QTmax: QT interval, QTmaxc: corrected QT interval, PACs: premature atrial complexes 
 
 
QTmax PACs 
0 min r = 0.53* 
15 min r = 0.44* 
30 min r = 0.41* 
240 min r = 0.27* 
2 hours after treatment r = 0.37* 
QTmaxc PACs 
0 min r = 0.46* 
15 min r = 0.47* 
30 min r = 0.46* 
240 min r =0.39* 
2 hours after treatment r = 0.52* 
 
 
 
